Accessibility Menu
Kazia Therapeutics logo

Kazia Therapeutics(NASDAQ) KZIA

Market Cap$159.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)-99%
5 Year-97%
1 Year+72%
1 Month+3%
$14.26
+2.70%
+0.38Today
After hours$14.09-$0.17 (-1.19%)
Kazia Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 13.952026-08-10
Kazia Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+12.41%USD 12.412026-08-03
1 month+2.88%USD 13.562026-07-10
3 month-2.45%USD 14.302026-05-12
Year to date+102.47%USD 6.892025-12-31
1 year+71.8%USD 8.122025-08-08
3 year-70.94%USD 48.002023-08-11
5 year-96.85%USD 442.892021-08-11
Since inception-99.47%USD 2,632.401999-01-06

Kazia Therapeutics Financials at a Glance

Market Cap

$159.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.52M

Net Income (TTM)

-A$50.68M

EPS (TTM)

-$6.82

P/E Ratio

-2.05

Dividend

$0.00

Beta (Volatility)

1.08 (Average)

Price

$14.26

Volume

210,865.524

Open

$13.78

Previous Close

$13.95

Daily Range

$13.78 - $14.82

52-Week Range

$4.86 - $17.40

Estimated Earnings Date

Sep 4, 2026

KZIA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kazia Therapeutics

Kazia Therapeutics Ltd is an oncology-focused biotechnology company based in Sydney, Australia. The company specializes in developing innovative therapies for various types of cancer, with a strong emphasis on brain tumors.

Products and Services
  • Paxalisib: A brain-penetrant inhibitor in clinical trials for glioblastoma and other CNS tumors
  • EVT801: A selective inhibitor targeting advanced solid tumors and ovarian cancer
  • Collaborations with leading research institutions and pharmaceutical companies to enhance drug development
Growth Outlook
  • Ongoing Phase II/III trials for paxalisib show promise in treating glioblastoma
  • Expansion into additional cancer types, including triple-negative breast cancer
  • Strong partnerships with organizations like Genentech and Evotec to accelerate research
Financial Highlights
  • Recent quarterly revenue of $0, reflecting ongoing investment in R&D
  • Cash and cash equivalents of approximately $69.39 million, providing a solid financial foundation
  • Trailing twelve months (TTM) net income of -$12.32 million, indicating significant R&D expenditures
Kazia Therapeutics is positioned in a high-growth sector, focusing on innovative cancer treatments. The company's lead candidate, paxalisib, is currently undergoing critical clinical trials, which could significantly impact its market position. With a robust cash reserve, Kazia is well-equipped to continue its research and development efforts. The collaborations with prominent organizations further enhance its potential for success in the competitive biotechnology landscape. Investors may find Kazia Therapeutics an intriguing opportunity as it navigates the complexities of drug development in oncology.
AI Generated • Jul 21, 2026

Industry

Biotechnology

Sector

Health Care

CEO

John E. Friend, II, MD

Website

www.kaziatherapeutics.com

Headquarters

Sydney, NSW 2000, AU

KZIA Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-92086.45%

Net Income Margin

-113004.58%

Return on Equity

-116.86%

Return on Capital

N/A

Return on Assets

-31.35%

Earnings Yield

-48.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$159.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.43M

Volume

210.87K

Avg. Volume

193.77K

Financials (TTM)

Gross Profit

A$2.52M

Operating Income

-A$47.10M

EBITDA

-A$45.23M

Operating Cash Flow

-A$20.67M

Capital Expenditure

A$4.14M

Free Cash Flow

-A$16.53M

Cash & ST Invst.

A$69.39M

Total Debt

A$98.71K

Kazia Therapeutics Performance Analysis

Kazia Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 0N/A
20232023-06-30AUD 0N/A
20242024-06-30AUD 1,512,606N/A
20252025-06-30AUD 27,201-98.2%
Kazia Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3049619800.0%
Q22024-12-31-99.1%
Q42025-06-30-11.6%
Q22025-12-31-100.0%
Kazia Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -68.48N/A
20232023-06-30AUD -37.35-45.5%
20242024-06-30AUD -33.28-10.9%
20252025-06-30AUD -12.23-63.2%
Kazia Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-69.6%
Q22024-12-3180.3%
Q42025-06-30-4.1%
Q22025-12-3138.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

A$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$159.41MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$26.57M

N/A

Employees

6

N/A

Net Income

-A$12.32M

-39.7%

EBITDA

-A$13.30M

-67.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$69.39M

+1847.8%

Total Debt

A$98.71K

-72.5%

Accounts Receivable

A$315.23K

+382.0%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$98.71K

-72.5%

Return on Assets

-31.35%

N/A

Return on Invested Capital

-38.87%

N/A

Free Cash Flow

-A$9.07M

-43.2%

Operating Cash Flow

-A$9.07M

-43.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNSPCNS Pharmaceuticals, Inc.
$5.13-4.65%
SNGXSoligenix, Inc.
$0.38-3.72%
SILOSilo Pharma, Inc.
$3.78+1.20%
TTNPTitan Pharmaceuticals, Inc.
$2.34-11.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$138.74+0.04%
ACHRArcher Aviation
$6.26+0.12%
NVDANvidia
$217.55-0.03%
INTCIntel
$97.52-0.04%

Questions About KZIA

What is the current price of Kazia Therapeutics?

Kazia Therapeutics is trading at $13.95 per share.

What is the 52-week range for Kazia Therapeutics?

Over the past 52 weeks, Kazia Therapeutics has traded between $4.86 and $17.40.

How much debt does Kazia Therapeutics have?

As of the most recent reporting period, Kazia Therapeutics reported total debt of A$259.52K.

How much cash does Kazia Therapeutics have on hand?

Kazia Therapeutics reported A$2.85M in cash and cash equivalents in its most recent financial results.

What is Kazia Therapeutics’s dividend yield?

Kazia Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services